Loading …

Idera Pharmaceuticals merged with Aceragen, Inc, a rare disease biopharmaceutical company, in September 2022. Aceragen subsequently began its wind-down in mid-2023.
Annual Revenue$1M to $5M
Estimated OwnershipPublicBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.